Amylyx Pharmaceuticals has entered into an underwriting agreement to sell 17,142,857 shares of its common stock at $3.50 per share, potentially raising about $56.9 million, or $65.5 million if an additional option is exercised; the proceeds will be used for commercialization and pipeline programs.